NCT04229927

BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease

A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of BPDO-1603 in Patients With Moderate-to-severe Alzheimer's Disease

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 712 (estimated)
• Sponsor: Hyundai Pharmaceutical Co., LTD. · Industry
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, randomized, double-blind, active-controlled, phase III clinical trial to evaluate the efficacy and safety of BPDO-1603 in patients with moderate-to-severe Alzheimer's disease

Conditions

• Moderate-to-severe Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	BPDO-1603	Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug

Timeline

• Start date: 2020-02-27
• Primary completion: 2022-02-28
• Completion: 2023-03-01
• First posted: 2020-01-18
• Last updated: 2020-04-22

Locations

1 site across 1 country: South Korea